Christian Barro
YOU?
Author Swipe
View article: Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls
Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls Open
View article: Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis
Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis Open
Importance There is a lack of validated biomarkers for disability progression independent of relapse activity (PIRA) in multiple sclerosis (MS). Objective To determine how serum glial fibrillary acidic protein (sGFAP) and serum neurofilame…
View article: Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis Open
Higher levels of sGFAP correlated with subsequent progression, particularly in nonactive patients, whereas sNfL reflected acute disease activity in patients with MS at high risk of underlying progressive pathology. Thus, sGFAP and sNfL lev…
View article: Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study
Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <span>NfL</span> and <span>pNfH</span>: A Longitudinal Multicentre Study Open
Objective Although the presymptomatic stages of frontotemporal dementia (FTD) provide a unique chance to delay or even prevent neurodegeneration by early intervention, they remain poorly defined. Leveraging a large multicenter cohort of ge…
View article: Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort
Central nervous system atrophy predicts future dynamics of disability progression in a real‐world multiple sclerosis cohort Open
Background and purpose In an era of individualized multiple sclerosis (MS) patient management, biomarkers for accurate prediction of future clinical outcomes are needed. We aimed to evaluate the potential of short‐term magnetic resonance i…
View article: Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS Open
Background: Alemtuzumab efficacy and safety was demonstrated in CARE-MS I and extension studies (CAMMS03409; TOPAZ). Objective: Evaluate serum neurofilament light chain (sNfL) in CARE-MS I patients and highly active disease (HAD) subgroup,…
View article: Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum
Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum Open
Background: There is an emerging evidence of the role of the microbiome in neurological diseases. Endotoxin is a component of gram-negative bacteria and thought to be one of the possible signals between the gut microbiota and the immune sy…
View article: Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum
Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum Open
View article: Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis
Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis Open
Background: Sensitive and specific biomarkers for use in progressive multiple sclerosis (MS) have not been established. We investigate neurofilament light (NfL) as a treatment response biomarker in progressive MS. Objective: To evaluate wh…
View article: Classification of multiple sclerosis based on patterns of<scp>CNS</scp>regional atrophy covariance
Classification of multiple sclerosis based on patterns of<span>CNS</span>regional atrophy covariance Open
There is evidence that multiple sclerosis (MS) pathology leads to distinct patterns of volume loss over time (VLOT) in different central nervous system (CNS) structures. We aimed to use such patterns to identify patient subgroups. MS patie…
View article: Fingolimod in children with Rett syndrome: the FINGORETT study
Fingolimod in children with Rett syndrome: the FINGORETT study Open
Background Rett syndrome (RS) is a severe neurodevelopmental disorder for which there is no approved therapy. This study aimed to assess safety and efficacy of oral fingolimod in children with RS using a pre-post and case–control design. M…
View article: Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)
Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003) Open
Background High‐dose pharmaceutical‐grade biotin (MD1003) has positive effects on disability in progressive multiple sclerosis (PMS), but its mechanism of action remains unclear. The objective of our study was to quantify the effect of MD1…
View article: Author response for "Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)"
Author response for "Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)" Open
View article: Blood neurofilament light: a critical review of its application to neurologic disease
Blood neurofilament light: a critical review of its application to neurologic disease Open
Neuronal injury is a universal event that occurs in disease processes that affect both the central and peripheral nervous systems. A blood biomarker linked to neuronal injury would provide a critical measure to understand and treat neurolo…
View article: Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease
Serum Neurofilament Light Chain Is Associated with Incident Lacunes in Progressive Cerebral Small Vessel Disease Open
Background and Purpose Serum neurofilament light (NfL)-chain is a circulating marker for neuroaxonal injury and is also associated with severity of cerebral small vessel disease (SVD) cross-sectionally. Here we explored the association of …
View article: Author response for "Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)"
Author response for "Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)" Open
View article: Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice
Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice Open
View article: Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis Open
Elevated pNfL levels at early stages of MS are associated with an increased risk of reaching sustained disability worsening. Hence, pNfL may serve as a prognostic tool to assess the risk of developing permanent disability in MS.
View article: Serum neurofilament light chain and optical coherence tomography measures in MS
Serum neurofilament light chain and optical coherence tomography measures in MS Open
This study provides Class III evidence that sNfL levels were associated with MS neurodegeneration measured by OCT.
View article: Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis Open
sNfL is a useful biomarker for monitoring disease activity and treatment response in pediatric MS. It is most likely helpful to predict disease severity and to guide treatment decisions in patients with pediatric MS. This study provides Cl…
View article: Vitamin D, smoking, EBV, and long-term cognitive performance in MS
Vitamin D, smoking, EBV, and long-term cognitive performance in MS Open
Lower vitamin D and smoking after clinical onset predicted worse long-term cognitive function and neuronal integrity in patients with MS.
View article: Monitoring of radiologic disease activity by serum neurofilaments in MS
Monitoring of radiologic disease activity by serum neurofilaments in MS Open
Low sNfL levels (≤30th percentile) help identify patients with MS with very low probability of recent radiologic disease activity during the preceding year. This result suggests that in future, sNfL assessment may substitute the need for a…
View article: Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Blood neurofilament light levels segregate treatment effects in multiple sclerosis Open
Choice of DMT in RRMS is significantly associated with degree of reduction in pNfL, which supports a role for pNfL as a drug response marker.
View article: Serum neurofilament light levels in normal aging and their association with morphologic brain changes
Serum neurofilament light levels in normal aging and their association with morphologic brain changes Open
Neurofilament light (NfL) protein is a marker of neuro-axonal damage and can be measured not only in cerebrospinal fluid but also in serum, which allows for repeated assessments. There is still limited knowledge regarding the association o…
View article: Growth differentiation factor 15 is increased in stable MS
Growth differentiation factor 15 is increased in stable MS Open
Serum GDF-15 concentrations are increased in patients with MS with a stable disease course. These data suggest that GDF-15 may serve as a biomarker for disease stability in MS.
View article: NfL and pNfH are increased in Friedreich’s ataxia
NfL and pNfH are increased in Friedreich’s ataxia Open
View article: Neurofilaments as blood biomarkers at the preataxic and ataxic stage of spinocerebellar ataxia type 3: a cross-species analysis in humans and mice
Neurofilaments as blood biomarkers at the preataxic and ataxic stage of spinocerebellar ataxia type 3: a cross-species analysis in humans and mice Open
Spinocerebellar ataxia type 3 (SCA3) is a devastating multisystemic neurodegenerative disease for which targeted molecular therapies are coming into reach (e.g. antisense oligonucleotides). To pave the way for upcoming translational trials…
View article: Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort – a prospective cohort study
Impact of parturition on maternal cardiovascular and neuronal integrity in a high risk cohort – a prospective cohort study Open
View article: Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis Open
Background: Neurofilament light chain (NfL) is a promising marker of disease activity/treatment response in multiple sclerosis (MS), although its predictive value for long-term clinical outcomes remains unclear. Objective: We measured NfL …
View article: Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis Open
The levels of sNfL were increased 6 years before the clinical MS onset, indicating that MS may have a prodromal phase lasting several years and that neuroaxonal damage occurs already during this phase.